Pharmaceutical care of a patient after liver transplantation treated with Tacrolimus
ZHANG Xinyue1 WANG Haigang2 WANG Hao3 YANG Chuanwei1
1.Department of Pharmacy, the Fourth People’s Hospital of Jinan, Shandong Province, Jinan 250031, China;
2.Department of Clinical Pharmacy, Qilu Hospital of Shandong University, Shandong Province, Jinan 250012, China;
3.Department of Intensive Care, Qilu Hospital of Shandong University, Shandong Province, Jinan 250012, China
Abstract：To explore the positive effect of clinical pharmacists on improving rational drug use in patients after liver transplantation. Clinical pharmacists participated in the drug treatment process of a patient with multiple attempts to remove ventilator and tracheal intubation after liver transplantation, combined with the interaction between immunosuppressants and anti-infective drugs, assist physicians to monitor the blood concentration and interaction of tacrolimus, optimize the drug administration plan, and ensure the safety of individualized drug use for patients. After 37 days of treatment, the patient’s condition was effectively controlled. The ventilator was successfully removed and the tracheal cannula was removed. The patient was transferred to a general ward. Collaboration between clinical pharmacists and doctors can significantly improve drug safety and effectiveness and promote rational drug use through pharmaceutical care of patients.
张欣悦1 王海刚2 王昊3 杨传伟1. 他克莫司治疗1例肝移植术后患者的药学监护[J]. 中国医药导报, 2023, 20(14): 183-187.
ZHANG Xinyue1 WANG Haigang2 WANG Hao3 YANG Chuanwei1. Pharmaceutical care of a patient after liver transplantation treated with Tacrolimus. 中国医药导报, 2023, 20(14): 183-187.
[1] Jasper CA，Jacob MV. Mycophenolate mofetil，azathioprine and tacrolimus：mechanisms in rheumatology [J]. Nat Rev Rhe- umatol，2020，16（3）：167-178.
[2] 蔡宜朋，陈泉金，谢培华，等.五酯胶囊相交地儿硫卓对他克莫司血药浓度及安全性的影响[J].中国临床药理学与治疗学，2019，24（8）：910-915.
[3] Sánchez Fructuoso A，Ruiz JC，Franco A，et al. Effectiveness and safety of the conversion to MeltDose? extended-release tacrolimus from other formulations of tacrolimus in stable kidney transplant patients：A retrospective study [J]. Clin Transplant，2020，34（1）：e13767.
[4] Ling Q，Huang H，Han Y，et al. The tacrolimus-induced glucose homeostasis imbalance in terms of the liver：from bench to bedside [J]. Am J Transplant，2020，20：701-713.
[5] Holking G，Schutte-Nutgen K，Schmitz J，et al. A low tacrolimus concentration/dose ratio increases the risk for the development of acute calcineurin inhibitor-induced nephrotoxicity [J]. J Clin Med，2019，8（10）：1586.
[6] 冯玘，杨春兰，冯丽娟，等.肾移植患者基因多态性对五酯胶囊增加他克莫司血药浓度的影响[J].中国药房，2020，31（4）：477-484.
[7] 秦伟，王晓雪，张相林，等.他克莫司浓度在移植患者全血、血浆与血细胞中的相关研究[J].中国药房，2019，30（15）：2105-2110.
[8] Lu Z，Bonate P，Keirns J. Population pharmacokinetics of immediate-and prolonged-release tacrolimus formulations in liver，kidney and heart transplant recipients [J]. Br J Clin Pharmacol，2019，85（8）：1692-1703.
[9] Wang L，Liu LH，Tong WH，et al. Effect of CYP3A5 gene polymorphisms on tacrolimus concentration /dosage ratio in adult liver patients [J]. Genet Mol Res，2015，14（4）：15148- 15157.
[10] 中国医师协会器官移植医师分会，中华医学会器官移植学分会.中国肝癌肝移植临床实践指南（2018版）[J].临床肝胆病杂志，2019，35（2）：275-280.
[11] 古杰，蒋文涛，李江，等.肝移植治疗终末期自身免疫性肝病的临床分析[J].中华危重病急救医学，2019，31（11）：1401-1405.
[12] 中华医学会器官移植学分会.他克莫司在临床肝移植中的应用指南[J].临床肝胆病杂志，2015，31（9）：1372-1374.
[13] Feng X，Shi Y，Ding Y，et al. Inhibitory effects of traditional Chinese medicine colquhounia root tablet on the pharmacokinetics of tacrolimus in rats [J]. J Ethnopharmacol，2022， 294：115358.
[14] Vanhove T，Bouwsma H，Hilbrands L，et al. Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients [J]. Am J Transplant，2017，17（9）：2372-2380.
[15] 石炳毅.中国实体器官移植受者侵袭性真菌病临床诊治指南（2016年版）（续）[J].中华器官移植杂志，2016，37（6）：368-372.
[16] Raman V，Shimin Z，Timothy G，et al. Voriconazole Inhibition of the Metabolism of Tacrolimus in a Liver Transplant Recipient and in Human Liver Microsomes [J]. Antimicrob Agents Chemother，2002，46（9）：3091-3093.
[17] Li C，Lu J，Zhou S，et al. Influential Factors and Efficacy Analysis of Tacrolimus Concentration After Allogeneic Hematopoietic Stem Cell Transplantation in Children with β-Thalassemia Major [J]. Pharmgenomics Pers Med，2021， 14：1221-1237.
[18] 张璠璠，李华茵，蔡映云，等.临床药师参与1例氟康唑致他克莫司血药浓度升高患者管理的药学监护[J].上海医药，2019，40（15）：82-112.
[19] Daniel EF，Lawrence SK，Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors：Expert Review and Best Practic Advice From the American Gastroenterological Association [J]. Gastroenterology，2017，152：706- 715.
[20] Fu R，Tajima S，Suetsugu K，et al. Biomarkers for individualized dosage adjustments in immunosuppressive therapy using calcineurin inhibitors after organ transplantation [J]. Acta Pharmacol Sin，2019，40（2）：151-159.
[21] 赵翊畅，侯静静，颜苗.肾移植受者联合用药对他克莫司影响及其剂量调整策略[J].药学进展，2021，45（2）：112-118.
[22] Itagaki F，Homma M，Yuzawa K，et al. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations [J]. J Pharm Pharmacol ，2004，56（8），1055-1059.
[23] 中华人民共和国国家卫生健康委员会.质子泵抑制剂临床应用指导原则（2020年版）[J].中国实用乡村医生杂志，2021，28（1）：1-9.
[24] Nashan B， Schemmer P， Braun F，et al. Early Everolimus-Facilitated Reduced Tacrolimus in Liver Transplantation：Results From the Randomized HEPHAISTOS Trial [J]. Liver Transpl，2022，28（6）：998-1010.
[25] Tang XY，Wu S，Wang D，et al. Human organoids in basic research and clinical applications [J]. Signal Transduct Target Ther，2022，7（1）：168.
[26] 张良灏，徐庆国，王新，等.劈离式肝移植术后肝再生的影响因素及其对预后的影响[J].中华肝胆外科杂志，2022，28（6）：413-418.
[27] 代星，高犇，张欣欣，等.肝移植术后早期并发症风险预测模型的建立与评价[J].临床肝胆病杂志，2022，38（2）402-408.
[28] 巫殷梅，张胜锋，黄寨，等.供体高钠血症对肝移植患者术后胃肠功能,肝功能以及远期预后的影响[J].现代消化及介入诊疗，2022，27（2）：215-219.
京公网安备 11010502046598号